Review
Efficacy and safety of fasinumab in the treatment of osteoarthritis
H. Kou1, B. Chen2
- College of Acumox and Tuina, Guizhou University of Traditional Chinese Medicine, Gui Yang, Guizhou, China.
- College of Acumox and Tuina, Guizhou University of Traditional Chinese Medicine, Gui Yang, Guizhou, China. chenbomed@163.com
CER18659
Review
PMID: 40658489 [PubMed]
Received: 27/02/2025
Accepted : 12/05/2025
In Press: 04/07/2025
Abstract
OBJECTIVES:
The aim of this meta-analysis and systematic review was to evaluate the clinical efficacy and safety of fasinumab in the treatment of osteoarthritis.
METHODS:
RevMan 5.4 was utilised to conduct a meta-analysis after relevant data on randomised controlled trials of therapeutic interventions for patients with osteoarthritis were gathered from literature databases such as PubMed, Embase, Web of Science, and the Cochrane Library.
RESULTS:
A total of 7 randomised controlled studies were included, including 32407 patients with osteoarthritis. Meta-analysis showed that compared with the control group, fasinumab intervention yielded more benefit, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain (3 mg, week 8) (MD = -0.88, 95% CI [-1.22 to -0.53]; Z=5.04; p<0.00001), WOMAC pain (3 mg, week 16) (MD = -0.72, 95% CI [-1.34 to -0.10]; Z=2.27; p=0.02), WOMAC function (3 mg, week 8) (MD = -1.02, 95% CI [-1.36 to -0.69]; Z=6.05; p<0.00001) and WOMAC function (3 mg, week 16) (MD = -0.97, 95% CI [-1.35 to -0.59]; Z=4.98; p<0.00001).
CONCLUSIONS:
Fasinumab is a monoclonal antibody medication used to treat osteoarthritis and lessen pain. Fasinumab enhanced scores on the WOMAC function, WOMAC pain subscale, and numerical rating scale. Naturally, one cannot overlook the restrictions or difficulties brought on by limited sample sizes and demographic variety. Future research should promote the inclusion of bigger populations and larger sample sizes in order to develop an osteoarthritis treatment that is both affordable and effective.
